Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn's disease

被引：0
|
作者：
Matar, M. [1 ,2 ]
Shamir, R. [1 ,2 ]
Turner, D. [3 ,4 ]
Broide, E. [5 ]
Weiss, B. [6 ]
Ledder, O. [3 ,4 ]
Guz-Mark, A. [1 ,2 ]
Rinawi, F. [1 ,2 ]
Cohen, S. [7 ]
Olivestone, C. Topf [8 ]
Shaul, R. [9 ]
Ben-Horin, S. [10 ]
Assa, A. [1 ,2 ]
机构：
[1] Schneider Childrens Hosp, Petah Tiqwa, Israel
[2] Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel
[3] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Jerusalem, Israel
[4] Juliet Keidan Inst Pediat Gastroenterol, Jerusalem, Israel
[5] Shamir Assaf Harofeh Med Ctr, Pediat Gastroenterol Unit, Zerifin, Israel
[6] Edmond & Lily Safra Childrens Hosp, Pediat Gastroenterol Unit, Ranat Gan, Israel
[7] Dana Dwek Childrens Hosp, Tel Aviv Sourasky Med Ctr, Pediat Gastroenterol Unit, Tel Aviv, Israel
[8] Kaplan Med Ctr, Pediat Gastroenterol Unit, Rehovot, Israel
[9] Rambam Med Ctr, Pediat Gastroenterol Unit, Haifa, Israel
[10] Sheba Med Ctr, Dept Gastroenterol, Ramat Gan, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P718
引用
收藏
页码：S578 / S579
页数：2
相关论文
共 50 条
  • [1] Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
    Matar, Manar
    Shamir, Raanan
    Turner, Dan
    Broide, Efrat
    Weiss, Batia
    Ledder, Oren
    Guz-Mark, Anat
    Rinawi, Firas
    Cohen, Shlomi
    Topf-Olivestone, Chani
    Shaoul, Ron
    Yerushalmi, Baruch
    Ben-Horin, Shomron
    Assa, Amit
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (11) : 1627 - 1635
  • [2] Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
    Cosnes, J.
    Sokol, H.
    Bourrier, A.
    Nion-Larmurier, I.
    Wisniewski, A.
    Landman, C.
    Marteau, P.
    Beaugerie, L.
    Perez, K.
    Seksik, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (10) : 1102 - 1113
  • [3] Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
    Christensen, B.
    Sparrow, M. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (01) : 178 - 179
  • [4] Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis
    Kopylov, U.
    Al-Taweel, T.
    Yaghoobi, M.
    Afif, W.
    Bitton, A.
    Lakatos, P. L.
    Ben-Horin, S.
    Seidman, E. G.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S50 - S51
  • [5] Adalimumab Monotherapy Versus Combination Therapy With Adalimumab and Immunomodulators for Crohn's Disease: A Meta-Analysis
    Kopylov, Uri
    Al-Taweel, Talal
    Yaghoobi, Mohammad
    Bitton, Alain
    Lakatos, Peter L.
    Ben-Horin, Shomron
    Seidman, Ernest G.
    Afif, Waqqas
    GASTROENTEROLOGY, 2014, 146 (05) : S201 - S201
  • [6] Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
    Osterman, Mark T.
    Sandborn, William J.
    Colombel, Jean-Frederic
    Robinson, Anne M.
    Lau, Winnie
    Huang, Bidan
    Pollack, Paul F.
    Thakkar, Roopal B.
    Lewis, James D.
    GASTROENTEROLOGY, 2014, 146 (04) : 941 - U464
  • [7] Crohn's Disease - Postoperative Recurrence: Adalimumab more effective than Standard Drugs
    Hofmann-Assmus, Marion
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (03): : 260 - 260
  • [8] Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
    Matsumoto, Takayuki
    Motoya, Satoshi
    Watanabe, Kenji
    Hisamatsu, Tadakazu
    Nakase, Hiroshi
    Yoshimura, Naoki
    Ishida, Tetsuya
    Kato, Shingo
    Nakagawa, Tomoo
    Esaki, Motohiro
    Nagahori, Masakazu
    Matsui, Toshiyuki
    Naito, Yuji
    Kanai, Takanori
    Suzuki, Yasuo
    Nojima, Masanori
    Watanabe, Mamoru
    Hibi, Toshifumi
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (11): : 1259 - 1266
  • [9] Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease
    Kariyawasam, Viraj C.
    Ward, Mark G.
    Blaker, Paul A.
    Patel, Kamal V.
    Goel, Rishi
    Sanderson, Jeremy D.
    Irving, Peter M.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) : 1555 - 1565
  • [10] Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
    Fiorino, Gionata
    Danese, Silvio
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (11): : 1257 - 1258
12345